Previous 10 | Next 10 |
Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma franchise including afami-cel and lete-cel in January 2024 Philadelphia, Pennsylvania. and Oxfo...
Adaptimmune Therapeutics plc (ADAP) is expected to report $-0.2 for Q3 2023
2023-11-08 11:45:19 ET Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Juli Miller – Investor Relations Adrian Rawcliffe – Chief Executive Officer Dennis Williams – Senior ...
2023-11-08 07:37:08 ET More on Adaptimmune Adaptimmune: Spinning Sarcoma Into Gold Seeking Alpha’s Quant Rating on Adaptimmune Historical earnings data for Adaptimmune Financial information for Adaptimmune For further details see: Adaptimmu...
Candidate is 10x more sensitive to target peptide than competitor candidates Entry into the clinic in 2024 Selection of approaches from next-gen toolbox in development Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 8, 2023) - Adaptimmune Therapeutics plc (NAS...
2023-11-07 11:53:09 ET More on Adaptimmune Adaptimmune: Spinning Sarcoma Into Gold Seeking Alpha’s Quant Rating on Adaptimmune Historical earnings data for Adaptimmune Financial information for Adaptimmune For further details see: Adaptimmu...
40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had clinical responses with lete-cel, by independent review [2] ; primary efficacy endpoint requires 16/60 patients have responses Median duration of response was ~11 months, data are imm...
~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of response of ~12 months ( CTOS 2022 ) Median overall survival (mOS) was ~17 months in SPEARHEAD-1 compared to historical mOS of <12 months for people with synovial sarcoma ...
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the third quarter ended September 30, 2023, befor...
35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across a broad range of solid tumors 50% response rate in 26 patients with ovarian, urothelial, and head & neck cancers 75% response rate in ovarian, urothelia...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...